An urgent need to anticipate tumor’s evolution & overcome immune evasion

An innovation to mimic patient’s cancer relapsing conditions.

AN URGENT NEED TO ANTICIPATE TUMOR'S EVOLUTION AND OVERCOME IMMUNE EVASION

An innovation to mimic patient’s cancer relapsing conditions

THE SUCCESFULL EQUATION TO ANTICIPATE DISEASE PROGRESSION

Multiple, adapted, and representative targets

1. Multiple, adapted, and representative targets
  • Qualitative Cancer-Related Proteins (CRP) overexpressed. By in vitro stimulation of selected allogeneic tumor cell lines with standards of care
    mimicking therapeutic pressure in the targeted indication.
  • 200 + Tumor Antigens related to stress, therapeutic pressure, and tumor plasticity.
    Identified from databases (including 6000 patient’s biopsies) and matching STC proteomic
    data.
  • Chemical tag ensuring recognition by the immune system.
    In vitro haptenation process to boost immune system activation.
  • Ghost cell process: dead cell with a whole membrane.
    Inactivating the cells into ghost cells to strengthen the immune response while maintaining
    safety.

PROVIDING A UNIQUE VALUE PROPOSAL IN THE FIELD

Providing a unique value proposal in the field. The successful equation to anticipate disease progression

READY TO USE,
STANDARDIZED AND SCALABLE

Defined biological material.

Pharmaceutical development in GMP conditions and pre-scale up validated .

QUICK GENERATION
OF FIRST-IN-CLASS THERAPIES

Propriatery science & patented platform protected in contries.

Limitless potential to generate a strong pipeline in solid tumors.

APCs MATURATION AND ACTIVATION

STC Internalisation by APCs (no HLA restriction). APC : antigen-presentinf cell, generally dentritic cell

t cell primming and activation by matured apcS

Recognition of MHC-peptide complex by TCRs

MHC : Major Histocompatibility complex
TCR : T-Cell Receptor

T-CELL EXPANSION

Expansion of the selected multi-specific T cell populations

destruction of patients tumor cells

  • Promotion of T cells infiltration into tumors
  • Infiltrating T cells recognize multiple tumor antigens linked to stress, treatment resistance, and plasticity 
  • Possible combination with immune checkpoint inhibitors (e.g anti CTLA-4, anti-PD-1…

LEVERAGING OUR PLATFORM TO GENERATE STRONG CANDIDATES

STC platform facilitates the quick generation of new STC treatments to meet patient’s needs in diverse solid tumors indication.

PHASE
R&D
PRECLINICAL
Regulatory
Phase I/II

STC – 1010 development: Strong scientific rationale to target other indications

STC- 1010

COLORECTAL CANCER

2nd CAUSE OF CANCER MORTALITY WORLDWIDE

mCRC 1L MSS : 95% of mCRC patients treated by chemotherapy (1st intention)
mCRC 2L MSI : 5% of mCRC patients treated by anti-PD1 immunotherapy
CRC Adjuvant ( Stages III-IV )

STC- 1010

OTHER INDICATIONS

Pancreatic - PADC
Liver disease - HCC
STC- 1010 x Companion Test

STC – 10XX development : Leveraging STC Platform to design first -in-class immuno – oncology products, anticiapting Specific cancers : Ovarian,Lung,Rare cancers…

STC- 1020

SOLID TUMOR

STC-1020 + Adjuvant

Our  response

STC-1010: our first candidate in metastatic colorectal cancer (mCRC)

01

To meet the need in anticipating treatment resistance

STC-1010 targets MSS and MSI-H population.

02

To meet the need in breaking immunue tolerance

STC-1010 has a robust and validated preclinical data pack showing:

INCREASE IN OVERALL SURVIVAL

in colorectal cold and hot mice model

INCREASE IN CD8+ TUMOR INFILTRATION

in several model

EFFICACY IN ANTI-PD1 RESISTANT

in colorectal cold and hot mice model

03

To meet the need for an accessible approach

An OFF-THE-SHELF technology allowing control of both time and cost of the manufacturing process.

“BreAK-CRC”, a frist-in-human clinical trial Phase I/IIA for STC-1010.

We are supported by leading figures in clinical immuno-oncology, with 9 early-phase centers committed to the next clinical trial.

“Cancer vaccines continue to show promising clinical results in solid tumors. STC-1010 is a new immunotherapeutic approach based on cancer vaccine mechanism of action for colorectal cancer patients.
In that, “BreAK-CRC” Study is eagerly expected :

 

CRC is still challenging as current immunotherapies were found only active
in dMMR/MSI-H “hot” CRC.

 

For the pMMR/MSS population, representing 95% of patients with CRC, there is an important medical need for drugs likely to heat up “cold” tumors and have a real impact for the patient.”

Pr. François GHIRINGHELLI MD, PhD
BreAK-CRC study coordinator

Director of the Early Clinical Unit CLIP2 INCA – CGFL DIJON FR
Director of UMR INSERM 1231 Head of TEAM 1, TIRECs: “Therapies and Immune REsponse
in CancerS” – University of Burgundy DIJON FR

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with broad & higher quality range of tumor antigens